VAXART (VXRT)
(Delayed Data from NSDQ)
$0.79 USD
-0.01 (-0.67%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.79 0.00 (0.50%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.79 USD
-0.01 (-0.67%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.79 0.00 (0.50%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth A Momentum C VGM
Zacks News
Vaxart (VXRT) Surges: Stock Moves 8.1% Higher
by Zacks Equity Research
Vaxart (VXRT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Vaxart Gets FDA Nod for Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Vaxart's (VXRT) investigational new drug application for oral coronavirus vaccine candidate gets a clearance from the FDA. The company will begin a phase I study later this month.
Do Options Traders Know Something About Vaxart (VXRT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Coronavirus Vaccine Efforts Key to Vaxart (VXRT) Q2 Earnings
by Zacks Equity Research
Vaxart (VXRT) has been working on developing a coronavirus vaccine. Increased clinical activity is expected to have increased expenses.
Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance
by Zacks Equity Research
Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vaxart (VXRT) has been actively engaged in developing a coronavirus vaccine. Investors are likely to focus on progress of vaccine program on the Q2 earnings call.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
3 Small Biotechs in Focus on Promising Coronavirus Vaccine Data
by Zacks Equity Research
Pfizer (PFE) and AstraZeneca (AZN) announce promising data from early-stage coronavirus vaccine studies. Here we discuss three leading biotechs with potential to recshare price gains.
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
by Zacks Equity Research
Vaxart's (VXRT) oral coronavirus vaccine candidate is chosen by Operation Warp Speed for a vaccine study. Last month, the company picked its lead COVID-19 vaccine candidate.
Vaxart (VXRT) Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
Vaxart (VXRT) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Implied Volatility Surging for Vaxart (VXRT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.
Biotech Stock Roundup: GILD Prices Remdesivir, VXRT Rises, ICPT Plunges & More
by Zacks Equity Research
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline developments.
Vaxart's Oral Coronavirus Vaccine Candidate Gets Chosen by OWS
by Zacks Equity Research
Vaxart's (VXRT) oral COVID-19 vaccine candidate is picked for a non-human primate challenge study as part of the Operation Warp Speed initiative to rapidly develop a vaccine against SARS-CoV-2.
Company News for Jun 29, 2020
by Zacks Equity Research
Companies in the news are: GPS, CLGX, AXSM, VXRT
Vaxart Gets New CEO, Focuses on Coronavirus Vaccine Program
by Zacks Equity Research
Vaxart (VXRT) management names Andrei Floroiu as its next chief executive officer with immediate effect. Stock appreciates on this news.
Emergent (EBS) Down on Unfavorable Patent Ruling on Narcan
by Zacks Equity Research
Emergent's (EBS) stock falls after a district court rules against the patent litigation on its Narcan nasal spray product. The court ruled in favor of Teva Pharmaceuticals, the defendants.
Stocks & ETFs Beneficiaries of Coronavirus Vaccine Ramp-Up
by Sanghamitra Saha
Efforts in formulating a coronavirus vaccine are heating up. These stocks and ETFs look to be the largest beneficiaries.
Emergent (EBS) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.
Vaxart (VXRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Vaxart's (VXRT) upcoming Q1 earnings call, investor focus will be on the company's progress with its oral vaccine candidates against SARS CoV-2.
Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
by Zacks Equity Research
Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.
Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Company News for Apr 22, 2020
by Zacks Equity Research
Companies In The News Are: SYF, VXRT, PAVM, WAFD
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Moderna, Sanofi, Vaxart and Eli Lilly